Background of the Lawsuit

A federal jury ruled that Amgen, along with its acquired subsidiary TenneoBio, intentionally infringed on Harbor's antibody patent. This patent covers key technology for the development of antibody-based therapeutics, making the infringement a significant legal and business risk. Harbor is a Dutch subsidiary of the Chinese company Harbor Biomed, and is actively strengthening its international patent portfolio.

Why the Verdict Was Reached

The core of the case was the similarity between the patent claims and Amgen's existing candidate substances. The court determined that the scope of the patent claims was clear and that Amgen had disregarded them, constituting intentional infringement. This reflects the strong stance of the U.S. court in protecting the rights of patent holders.

Implications for the Industry and Patients

Antibody therapeutics are a rapidly growing market in areas such as cancer and immune diseases, and patent disputes can directly impact development timelines and costs. Amgen may need to abandon the technology or renegotiate licensing agreements, potentially disrupting its pipeline. From a patient perspective, there is a risk of delays in the development of alternative treatments.

Market Reaction and Future Scenarios

The company's stock price is likely to fall sharply, and Amgen will need to reassess its future patent licensing costs. Harbor's victory in this case may lead it to strengthen patent claims against other biotech companies, potentially expanding legal risks across the industry. In the long term, patent strategies are expected to be revised, and negotiation costs are likely to increase.